University of Michigan: Scleroderma, Systemic trials
The registry lists 17 Scleroderma, Systemic studies with University of Michigan as lead sponsor. 1 are open to participants now and 4 have results posted.
Phase 1 1Phase 2 1Phase 4 1No phase 15(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Systemic Sclerosis DIet for GastrointESTinal SymptomsRecruitingNCT07402226Not applicable
- TENS in SclerodermaCompletedNCT06646913Not applicableResults posted
- Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)CompletedNCT03274076Phase 1/2Results posted
- Taking Charge of Systemic SclerosisCompletedNCT02494401Not applicableResults posted
- Scleroderma ARFI Imaging of the SkinCompletedNCT02006420Results posted
- Self-Guided Resilience-Building Energy Management to Enhance Well-being (RENEW) Intervention for People With Systemic Sclerosis (SSc)CompletedNCT07402863Not applicable
- RENEW-AI: Personalizing Scleroderma Management With an AI Health CoachCompletedNCT06999226Not applicable
- RENEW Scleroderma: A Peer-Mentored, Web Intervention for Resilience-based, Energy Management to Enhance Wellbeing and FatigueCompletedNCT04908943Not applicable
- Feasibility and Preliminary Effects of the Resilience-based, Energy Management to Enhance Wellbeing in Systemic Sclerosis (RENEW) InterventionCompletedNCT04588714Not applicable
- Rehabilitation for Arm Coordination and Hand Movement in Systemic SclerosisCompletedNCT03482219Not applicable
- Novel Rehabilitation Strategies to Improve Arm Function in Patients With SclerodermaCompletedNCT02837549Not applicable
- Novel Screening Strategies for Scleroderma PAHCompletedNCT01959815
- Probiotics in Patients With Moderate-to-severe Distention/ Bloating From Systemic SclerosisWithdrawnNCT01497743Phase 4
- Angiogenic/Angiostatic Mediators in Patients With Systemic SclerosisCompletedNCT00668473
- Stimulatory Autoantibodies to the Platelet-Derived Growth Factor Receptor (PDGFR) in Patients With Systemic SclerosisCompletedNCT00667134
- UVA1 Light for Treatment of Scleroderma and Similar ConditionsCompletedNCT00476801Not applicable
- UVA1 Light for Scleroderma and Similar ConditionsTerminatedNCT00476697Not applicable